ABSTRACT
CHD in postmenopausal women.
Synthetic progestogens bind to
progesterone receptors but exhibit differing
degrees of androgenicity. In general, C-21
steroids derived from progesterone have a high
affinity for progesterone receptors and have
minimal androgenic activity, whereas
progestogens derived from testosterone and
19-nortestosterone have more androgenic
activity. It is likely that the cardiovascular
effects of different progestogens are in part
related to their differing androgenicity.
